Analyst Ratings For Achaogen Inc (NASDAQ:AKAO)
Today, Stifel Nicolaus raised its price target on Achaogen Inc (NASDAQ:AKAO) to $22.00 per share.
There are 8 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Achaogen Inc (NASDAQ:AKAO) is Buy with a consensus target price of $21.75 per share, a potential 208.51% upside.
Some recent analyst ratings include
- 8/7/2018-Needham & Company LLC was Downgraded by analysts at Needham & Company LLC from a “Buy ” rating to a ” Hold” rating. They now have a N/A price target on the stock.
- 7/27/2018-Cowen Reiterated Rating of Buy.
- 5/7/2018-Guggenheim was Downgraded by analysts at Guggenheim from a “Buy ” rating to a ” Neutral” rating. They now have a $17.00 price target on the stock.
- 5/3/2018-Mizuho Reiterated Rating of Buy.
Recent Insider Trading Activity For Achaogen Inc (NASDAQ:AKAO)
Achaogen Inc (NASDAQ:AKAO) has insider ownership of 7.80% and institutional ownership of 68.74%.
- On 6/26/2018 Blake Wise, CEO, sold 1,194 with an average share price of $9.59 per share and the total transaction amounting to $11,450.46.
- On 6/26/2018 Gary Loeb, General Counsel, sold 324 with an average share price of $9.59 per share and the total transaction amounting to $3,107.16.
- On 6/26/2018 Janet Dorling, Insider, sold 450 with an average share price of $9.59 per share and the total transaction amounting to $4,315.50.
- On 6/26/2018 Tobin Schilke, CFO, sold 298 with an average share price of $9.59 per share and the total transaction amounting to $2,857.82.
- On 6/11/2018 Tobin Schilke, CFO, sold 2,087 with an average share price of $11.95 per share and the total transaction amounting to $24,939.65.
- On 5/3/2018 Robert W Duggan, Major Shareholder, bought 976,880 with an average share price of $11.33 per share and the total transaction amounting to $11,068,050.40.
- On 4/27/2018 Robert W Duggan, Major Shareholder, bought 102,849 with an average share price of $12.96 per share and the total transaction amounting to $1,332,923.04.
About Achaogen Inc (NASDAQ:AKAO)
Achaogen, Inc., a late-stage biopharmaceutical company, focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.
Recent Trading Activity for Achaogen Inc (NASDAQ:AKAO)
Shares of Achaogen Inc closed the previous trading session at 7,05 +0,19 2,77 % with 6.75 shares trading hands.